Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Sponsor: Revolution Medicines, Inc.
ClinicalTrials ID:NCT07491445
This Phase 3 study assesses daraxonrasib, alone or with gemcitabine and nab-paclitaxel, versus standard chemotherapy in metastatic pancreatic adenocarcinoma. Eligible patients are adults with confirmed metastatic disease, ECOG 0-1, and documented RAS status. Interventions include oral daraxonrasib and IV gemcitabine/nab-paclitaxel, focusing on progression-free and overall survival.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Description
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel will improve progression-free survival and/or overall survival compared with standard gemcitabine and nab-paclitaxel when given as first-line treatment in patients with metastatic pancreatic adenocarcinoma.
Patients will be randomized to one of three arms: daraxonrasib (Arm A), daraxonrasib + gemcitabine and nab-paclitaxel (Arm B), or gemcitabine and nab-paclitaxel (Arm C).
Eligibility Criteria
Inclusion Criteria
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.
- Documented RAS mutation status, either mutant or wild-type.
- Measurable disease per RECIST v1.1.
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- Able to take oral medications.
Exclusion Criteria
- Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.
- Active or known history of untreated central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to randomization.
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Dana-Farber Cancer Institute | 02215 | Boston | Massachusetts |
| Comprehensive Cancer Centers of Nevada | 89052 | Henderson | Nevada |
| Taylor Cancer Research Center | 43537 | Maumee | Ohio |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.